SCHEMBL14940944

SCHEMBL14940944

NC(=O)C1CCCN1C[C]=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.39
SPHK1 Q9NYA1 1/20 0.39
SCN3A Q9NY46 1/20 0.37
LMNA P02545 2/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
AR P10275 1/20 0.34
GRM2 Q14416 1/20 0.33
DPP4 P27487 1/20 0.32
ACE P12821 3/20 0.32
KDM4E B2RXH2 1/20 0.32
F2 P00734 1/20 0.32
REN P00797 1/20 0.32
LTA4H P09960 1/20 0.32
MAPT P10636 1/20 0.32
PEPD P12955 1/20 0.32
ALOX15 P16050 1/20 0.32
PTGS1 P23219 1/20 0.32
HTR2A P28223 1/20 0.32
PTGS2 P35354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872381 0.84 AR (0.39) POLBSPHK1SCN3ALMNAMAOA
SCHEMBL2355066 0.83 ACE (0.42) LMNAACEKDM4EF2REN
SCHEMBL5872372 0.79 AR (0.35) POLBSPHK1SCN3ALMNAMAOA
SCHEMBL12201786 0.79 POLB (0.42) POLBSPHK1SCN3ALMNAMAOA
SCHEMBL943039 0.79 POLB (0.42) POLBSPHK1SCN3ALMNAMAOA
SCHEMBL19897429 0.78 SMN1; SMN2 (0.43) LMNAACEKDM4EF2REN
SCHEMBL19897437 0.78 SMN1; SMN2 (0.43) LMNAACEKDM4EF2REN
SCHEMBL19897426 0.78 SMN1; SMN2 (0.43) LMNAACEKDM4EF2REN
SCHEMBL7300215 0.77 POLB (0.41) POLBSPHK1SCN3ALMNAMAOA
SCHEMBL16129826 0.77 POLB (0.41) POLBSPHK1SCN3ALMNAMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC, 2014-10-16 US claimed
EP-2776407-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2014-09-17 EP claimed
WO-2013070657-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-05-16 WO claimed
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC, 2014-10-16 US disclosed
EP-2776407-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2014-09-17 EP disclosed
WO-2013070657-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309192-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO MRGPRX1, MRGPRX2, AGTR1 POLB 4595/4885SPHK1 750/4885SCN3A 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.